SCHEMBL2174365

SCHEMBL2174365

Cc1ccn(-c2ccc(N3CCCC3)cc2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.51
MAPT P10636 6/20 0.47
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
ATM Q13315 1/20 0.47
AVPR2 P30518 3/20 0.47
OXTR P30559 3/20 0.47
AVPR1A P37288 3/20 0.47
ALDH1A1 P00352 6/20 0.45
KDM4E B2RXH2 5/20 0.45
GAA P10253 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALOX15 P16050 2/20 0.45
NR4A1 P22736 1/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CHKA P35790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12422701 0.78 HTT (0.59) HTTMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL22465874 0.78 CHKA (0.44) HTTMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL22466158 0.76 ALDH1A1 (0.44) HTTMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL18725064 0.76 HTT (0.58) HTTMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL597553 0.75 HTT (0.56) HTTMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL3094889 0.75 HTT (0.56) HTTMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL2615994 0.75 HTT (0.56) HTTMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL5539090 0.75 HTT (0.56) HTTMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL5544146 0.75 HTT (0.56) HTTMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL1353764 0.75 HTT (0.56) HTTMAPTRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 US disclosed
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases LNCYTE CORPORATION (US) 2008-07-10 US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 HTT 1826/4885MAPT 2590/4885RAB9A 2928/4885
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases MMP25, MMP9, MMP24 HTT 2524/4885MAPT 3223/4885RAB9A 2400/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 HTT 1990/4885MAPT 2732/4885RAB9A 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.